Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Cuts Target Price to $5
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating
A Quick Look at Today's Ratings for Mersana Therapeutics(MRSN.US), With a Forecast Between $6 to $8
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Positive Outlook for Mersana Therapeutics Driven by Promising XMT-1660 Developments and Strategic Focus